RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0295167 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Burenjargal Batmunkh und 32 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The SARS-CoV-2 vaccination campaign began in February 2021 and achieved a high rate of 62.7% of the total population fully vaccinated by August 16, 2021, in Mongolia. We aimed to assess the initial protective antibody production after two doses of a variety of types of SARS-CoV-2 vaccines in the Mongolian pre-vaccine antibody-naïve adult population. This prospective study was conducted from March-April to July-August of 2021. All participants received one of the four government-proposed COVID-19 vaccines including Pfizer/BioNTech (BNT162b2), AstraZeneca (ChAdOx1-S), Sinopharm (BBIBP-CorV), and Sputnik V (Gam-COVID-Vac). Before receiving the first shot, anti-SARS-CoV-2 S-RBD human IgG titers were measured in all participants (n = 1833), and titers were measured 21–28 days after the second shot in a subset of participants (n = 831). We found an overall average protective antibody response of 84.8% (705 of 831 vaccinated) in 21–28 days after two doses of the four types of COVID-19 vaccines. Seropositivity and titer of protective antibodies produced after two shots of vaccine were associated with the vaccine types, age, and residence of vaccinees. Seropositivity rate varied significantly between vaccine types, 80.0% (28 of 35) for AstraZeneca ChAdOx1-S; 97.0% (193 of 199) for Pfizer BNT162b2; 80.7% (474 of 587) for Sinopharm BBIBP-CorV, and 100.0% (10 of 10) for Sputnik V Gam-COVID-Vac, respectively. Immunocompromised vaccinees with increased risk for developing severe COVID-19 disease had received the Pfizer vaccine and demonstrated a high rate of seropositivity. A high geometric mean titer (GMT) was found in vaccinees who received BNT162b2, while vaccinees who received ChAdOx1-S, Sputnik V, and BBIBP-CorV showed a lower GMT. In summary, we observed first stages of the immunization campaign against COVID-19 in Mongolia have been completed successfully, with a high immunogenicity level achieved among the population with an increased risk for developing severe illness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia.
- National Center for Communicable Diseases of Mongolia, Ulaanbata, Mongolia.
- School of Public Health, Mongolian National University of Medical Sciences, Sainshand, Mongolia.
- School of Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia.
- International School of Mongolian Medicine, Mongolian National University of Medical Sciences, Sainshand, Mongolia.
- School of Nursing, Mongolian National University of Medical Sciences, Sainshand, Mongolia.
ORCID-Profile: Shatar Shaarii, Nansalmaa Khaidav, Gansukh Choijilsuren, Enkh-Amar Boldbaatar, Tsogtsaikhan Sandag
Zitieren
APA
Batmunkh, B., Otgonbayar, D., Shaarii, S., Khaidav, N., Shagdarsuren, O. E., Boldbaatar, G., Danzan, N. E., Dashtseren, M., Unurjargal, T., Dashtseren, I., Dagvasumberel, M., Jagdagsuren, D., Bayandorj, O., Biziya, B., Surenjid, S., Togoo, K., Bat-Erdene, A., Narmandakh, Z., Choijilsuren, G., …, & Sandag, T. (2023). RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia. PLOS ONE. https://doi.org/10.1371/journal.pone.0295167
Vancouver
Batmunkh B, Otgonbayar D, Shaarii S, Khaidav N, Shagdarsuren OE, Boldbaatar G, et al. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia. PLOS ONE. 2023. doi:10.1371/journal.pone.0295167
BibTeX
@article{Batmunkh2023,
author = {Batmunkh, Burenjargal and Otgonbayar, Dashpagma and Shaarii, Shatar and Khaidav, Nansalmaa and Shagdarsuren, Oyu-Erdene and Boldbaatar, Gantuya and Danzan, Nandin-Erdene and Dashtseren, Myagmartseren and Unurjargal, Tsolmon and Dashtseren, Ichinnorov and Dagvasumberel, Munkhbaatar and Jagdagsuren, Davaalkham and Bayandorj, Oyunbileg and Biziya, Baasanjargal and Surenjid, Seesregdorj and Togoo, Khongorzul and Bat-Erdene, Ariunzaya and Narmandakh, Zolmunkh and Choijilsuren, Gansukh and Batmunkh, Ulziisaikhan and Soodoi, Chimidtseren and Boldbaatar, Enkh-Amar and Byambatsogt, Ganbaatar and Byambaa, Otgonjargal and Deleg, Zolzaya and Enebish, Gerelmaa and Chuluunbaatar, Bazardari and Zulmunkh, Gereltsetseg and Tsolmon, Bilegtsaikhan and Gunchin, Batbaatar and Chimeddorj, Battogtokh and Dambadarjaa, Davaalkham and Sandag, Tsogtsaikhan},
title = {RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0295167}
}
EUVIMED